drugset / Trial / NCT05636774
Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial
Completed
97 enrolled
University Hospital, Essen
Charite University, Berlin, Germany · collabUniversity Hospital Heidelberg · collabUniversity Hospital Homburg/Saar · collabUniversitätsklinikum Leipzig · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The pathophysiological implications of various cancer diseases and anti-cancer therapies is the occurrence of a cardiac disease-like phenotype with cardiac dysfunction, cardiac wasting, and cardiac homeostasis changes (incl. fibrosis and apoptosis) in end-stage cancer patients, causing heart failure like syndrome with development of congestion, dyspnoea and severely reduced physical functioning. The present trial aims to evaluate, if a heart failure medication improves the self-care ability and self-reported health care status of patients with with advanced cancer receiving specialized palliative care.
Timeline
- Start
- 2022-12-12
- Primary completion
- 2025-01-31
- Completion
- 2025-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | — | — |
| Subject | Ferric carboxymaltose | Other / unclassified | — | — |
| Subject | Ivabradine | Small molecule | — | — |
| Subject | Sacubitril/valsartan | Unknown | — | — |
Indications
No indication recorded.